These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 3131431)

  • 1. In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections.
    Reed SG
    J Immunol; 1988 Jun; 140(12):4342-7. PubMed ID: 3131431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-specific Il-4- and IL-10-secreting CD4+ lymphocytes increase in vivo susceptibility to Trypanosoma cruzi infection.
    Barbosa de Oliveira LC; Curotto de Lafaille MA; Collet de Araujo Lima GM; de Almeida Abrahamsohn I
    Cell Immunol; 1996 May; 170(1):41-53. PubMed ID: 8660798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergism between tumor necrosis factor-alpha and interferon-gamma on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism.
    Muñoz-Fernández MA; Fernández MA; Fresno M
    Eur J Immunol; 1992 Feb; 22(2):301-7. PubMed ID: 1537373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage activity, IL-6 levels, antibody response and heart histology in rats undergoing an attenuated Trypanosoma cruzi acute infection upon treatment with recombinant interferon gamma.
    Revelli S; Didoli G; Roggero E; Moreno H; Bernabo J; Wietzerbin J; Bottasso O
    Cytokines Cell Mol Ther; 1998 Sep; 4(3):153-9. PubMed ID: 9825840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous IFN-gamma is required for resistance to acute Trypanosoma cruzi infection in mice.
    Torrico F; Heremans H; Rivera MT; Van Marck E; Billiau A; Carlier Y
    J Immunol; 1991 May; 146(10):3626-32. PubMed ID: 1902858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic analysis of antigen-specific immune responses in resistant and susceptible mice during infection with Trypanosoma cruzi.
    Hoft DF; Lynch RG; Kirchhoff LV
    J Immunol; 1993 Dec; 151(12):7038-47. PubMed ID: 8258708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation-induced T cell death exacerbates Trypanosoma cruzi replication in macrophages cocultured with CD4+ T lymphocytes from infected hosts.
    Nunes MP; Andrade RM; Lopes MF; DosReis GA
    J Immunol; 1998 Feb; 160(3):1313-9. PubMed ID: 9570549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmania sp: comparative study with Toxoplasma gondii and Trypanosoma cruzi in their ability to initialize IL-12 and IFN-gamma synthesis.
    Oliveira MA; Santiago HC; Lisboa CR; Ceravollo IP; Trinchieri G; Gazzinelli RT; Vieira LQ
    Exp Parasitol; 2000 Jun; 95(2):96-105. PubMed ID: 10910710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine and nitric oxide regulation of the immunosuppression in Trypanosoma cruzi infection.
    Abrahamsohn IA; Coffman RL
    J Immunol; 1995 Oct; 155(8):3955-63. PubMed ID: 7561103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-10 mediates susceptibility to Trypanosoma cruzi infection.
    Reed SG; Brownell CE; Russo DM; Silva JS; Grabstein KH; Morrissey PJ
    J Immunol; 1994 Oct; 153(7):3135-40. PubMed ID: 8089491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [TH1 response in the experimental infection with Trypanosoma cruzi].
    Cardoni RL; Antúnez MI; Abrami AA
    Medicina (B Aires); 1999; 59 Suppl 2():84-90. PubMed ID: 10668248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta.
    Gazzinelli RT; Oswald IP; Hieny S; James SL; Sher A
    Eur J Immunol; 1992 Oct; 22(10):2501-6. PubMed ID: 1396957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trypanosoma cruzi affects nitric oxide production by murine peritoneal macrophages.
    Pakianathan DR; Kuhn RE
    J Parasitol; 1994 Jun; 80(3):432-7. PubMed ID: 8195945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages.
    Hori K; Mihich E; Ehrke MJ
    Cancer Res; 1989 May; 49(10):2606-14. PubMed ID: 2496917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trypanosoma cruzi: IL-10, TNF, IFN-gamma, and IL-12 regulate innate and acquired immunity to infection.
    Abrahamsohn IA; Coffman RL
    Exp Parasitol; 1996 Nov; 84(2):231-44. PubMed ID: 8932773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential control of IFN-gamma and IL-2 production during Trypanosoma cruzi infection.
    Nabors GS; Tarleton RL
    J Immunol; 1991 May; 146(10):3591-8. PubMed ID: 1902857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trypanosoma cruzi: Tc52 released protein-induced increased expression of nitric oxide synthase and nitric oxide production by macrophages.
    Fernandez-Gomez R; Esteban S; Gomez-Corvera R; Zoulika K; Ouaissi A
    J Immunol; 1998 Apr; 160(7):3471-9. PubMed ID: 9531308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic protection by specific antibodies and interferon against infection by Trypanosoma cruzi in vitro.
    Plata F; Wietzerbin J; Pons FG; Falcoff E; Eisen H
    Eur J Immunol; 1984 Oct; 14(10):930-5. PubMed ID: 6208038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma.
    Murray HW; Spitalny GL; Nathan CF
    J Immunol; 1985 Mar; 134(3):1619-22. PubMed ID: 3918107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2.
    Duan X; Yonemitsu Y; Chou B; Yoshida K; Tanaka S; Hasegawa M; Tetsutani K; Ishida H; Himeno K; Hisaeda H
    Vaccine; 2009 Oct; 27(44):6154-9. PubMed ID: 19712768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.